-
Company Profile
![]()
Avacta Group Plc – Company Profile
Avacta Group Plc (Avacta) is a clinical-stage oncology drug company. Its technology platform includes Cision and Affimer which develops novel cancer therapies and biotherapeutics. The company’s pipeline products include AVA-6000, AVA-3996, AVA-28 and AVA-021. Avacta pipeline treats cancer and immune cytokines. It also carries out the TMAC platform. The company has operations across the UK. Avacta is headquartered in Wetherby, England, the UK.
Add to Basket -
Product Insights
New![]()
Avacta Group Plc Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Avacta Group Plc Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Avacta Group Plc (Avacta) is a developer of therapeutic molecules used in a wide range of life sciences applications in research and diagnostics. The company offers products that include optim and sensipod. It also develops UCB celltech which is an analytical instrument. Avacta’s sensipod is an in-clinical blood testing system that delivers ELISA tests. The company offers intellectual property...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.